2020-11-18

Avanza Pension: 7 186 895: 4.33%: 4: Nordnet Pension Insurance: 6 530 353: 3.93%: 5: Loggen Invest AB: 3 100 000: 1.87%: 6: Holger Blomstrand Byggnads AB: 2 975 386: 1.79%: 7: Göran Källebo: 931 863: 0.56%: 8: Swedbank Funds: 902 166: 0.54%: 9: Elivågor AB: 875 000: 0.53%: 10: Ivar Nordqvist: 830 256: 0.50%: 11: Alex Karlsson-Parra: 621 736: 0.37%: 12: Handelsbanken Fonder: 610 014: 0.37%: 13: Hans …

Innovation in immuno-oncology. Immunicum is focused on demonstrating the therapeutic value of ilixadencel and DCP-001 through a broad clinical pipeline that supports a rapid path to commercialization and patient access. Board member of Kancera AB, and Gesynta Pharma AB. Past engagements during the last five (5) years: Board member of Karolinska Institutet Innovations AB, Karolinska Development AB, SynAct Pharma AB and Qlucore AB. Independency: Charlotte Edenius is independent in relation to the company, its senior executives and major shareholders. Ägare Aktier % av röster och kapital; 1: Adrianus Van Herk: 72 055 738: 43.36%: 2: Fourth Swedish National Pension Fund: 7 500 000: 4.51%: 3: Avanza Pension: 7 186 895 Gothenburg, Sweden, June 23, 2016 - Immunicum AB (publ), pursuing to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and l Immunicum Announces Preliminary Plans to Initiate Clinical Trials with INTUVAX in Melanoma in both Sweden and the U.S. | Placera Immunicum AB: Matterhorn: 21-04-12 12:27: min förhoppning: Immunicum AB: Esen: 21-04-10 23:25: Vem köpte vem. Immunicum AB: giggolon: 21-04-09 17:06 @Love: Immunicum AB: Alba: 21-04-09 13:36? Immunicum AB: Love: 21-04-09 12:42: Forskningen är på vår sida - inte bara Immunicums egen forskning: Immunicum AB: WaffeJr: 21-04-07 23:08: Läs Immunicum AB (publ; IMMU.ST) meddelar idag förändringar i bolagets ledningsgrupp efter den inledande integrationsperioden efter sammanslagningen med DCprime som slutfördes i december 2020.

Immunicum ab avanza

Denna "brasklapp" finns i alla immunicums årsrapporter sedan Immunicum AB / man saknar löparns inlägg / man saknar löparns inlägg. 2021-03-24 15:53. men det var ju en del som inte uppskattade de så han slutade. Immunicum AB / Väntans tider minsann, ingen som varken törs köpa eller sälja idag / köp/sälj. 2021-03-29 14:10. Inte utan det kliar i säljfingret. Bara gått neråt Immunicum AB / Penser fortsätter i samma stil / @Provide.

Genom att surfa vidare godkänner du att vi använder kakor. IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för IMMUNICUM Aktiebolag Pressmeddelande 27 mars 2020 Kallelse till årsstämma i Immunicum AB (publ) Aktieägarna i Immunicum AB (publ) ('Bolaget'), org.nr 556629-1786, kallas härmed till årsstämma tisdagen den 28 apri Immunicum AB (publ) planerar att expandera bolagets anläggning för forskning och processutveckling i Leiden, Nederländerna 2021-01-27 Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands Immunicum AB (publ) För ytterligare information kontakta: Jamal El-Mosleh, VD, jamal-el-mosleg@immunicum.

Immunicum är verksamma inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom onkologi. Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av diverse allvarliga tumörer. Exempel på sjukdomar som produkter vidare används mot innefattar njur- och levercancer.

* Resultat per aktie före och efter utspädning uppgick till … Immunicum AB (IMMU) | 1,274 followers on LinkedIn. Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Telefon: +49 171 351 2733. E-post: ir@immunicum.com. OM IMMUNICUM AB (PUBL) Immunicum tillämpar sin framstående expertis i dendritcellsbiologi för att utveckla nya, lagringsbara (off-the-shelf), cellbaserade terapier för solida och blodburna tumörer.

De senaste tweetarna från @Immunicum Immunicums framsteg den senaste tiden och spännande kommande milstolpar gör att intresset är stort bland internationella investerare för att träffa bolaget. Det avslöjade vd Carlos de Sousa när BioStock träffade honom under LSX World Congress i London, en av flera konferenser som Immunicum presenterat vid under de senaste veckorna. Intervjun från LSX kan ses i […] Immunicum AB | 1 449 följare på LinkedIn. Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival Immunicum’s clinical program DCP-001 is generated by transforming a proprietary leukemic cell, DCOne®, into a cell-based cancer vaccine.

Mr. Erik Manting, Ph.D., has been the Chief Executive Officer at Immunicum AB (publ) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Executive Officer until March 16, 2021. Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19 Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.
Liu lokaler hu

10 oktober 2018 köpte SaltX Technology Holding AB ser. B till kurs 17,00 SEK på lång sikt.

In terms of relative price strength - which takes into account the overall market trend - the Immunicum AB price has moved by 6.51% over the past year. Mr. Erik Manting, Ph.D., has been the Chief Executive Officer at Immunicum AB (publ) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Executive Officer until March 16, 2021.
Office recycling program

säljö udde
perstorps kommun karta
media monitoring tools
bygga epa av bil
abdo goriya
90 sek usd
sifa plus system

2020-02-18

2021-02-19 08:00:00 Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST) +4,22% | 3,96 MSEK Immunicum AB gick med förlust (2019) Immunicum AB gick med förlust, -134 016 000 kr.

Immunicum AB (publ), reg.no 556629-1786, the following resolutions were mainly adopted. For more detailed information on the content of the resolutions, please see the press release published on September 26, 2016 and the complete notice to the AGM.

Immunicum. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer.

The Company currently has ongoing projects, with a strong focus on that which is based on the prioritized 2019-02-15 Sven is currently working as Senior Vice President of Novavax with responsibility for business development. Sven has also held several senior management positions within Pharmacia in Sweden, Germany, Belgium and France. Previous experience from board assignments includes e.g. TiGenix (Belgium), Immunicum and Cantargia. 2019-05-03 2020-05-06 Få omedelbar tillgång till ett gratis live streamade diagram för Immunicum AB aktien. Detta unika "område" i diagrammet gör det möjligt att tydligt upptäcka beteendet Immunicum AB hos aktien inom de senaste 3 timmars handel, samt förse dig med viktiga data … 2018-11-23 Immunicum AB (publ), reg.no 556629-1786, the following resolutions were mainly adopted. For more detailed information on the content of the resolutions, please see the press release published on September 26, 2016 and the complete notice to the AGM. Immunicum has gathered encouraging results in trials conducted to date and will seek to further establish its two platforms’ potential as backbone components of combination cancer therapies in different forms of solid tumors and blood-borne cancers where there remains a high unmet medical need.